Hypertension Management

Introduction

• Hypertension management involves lifestyle modifications and pharmacological interventions, as recommended by the American Heart Association 1, 2

Monitoring and Follow-up

• Check electrolytes and kidney function (eGFR) within 4 weeks of initiation and after any dose increase of chlorthalidone, as recommended by the American Journal of Kidney Diseases guidelines 3
• Follow up every 6-8 weeks until blood pressure goal is achieved, then every 3-6 months, according to the American Journal of Kidney Diseases guidelines 3
• Home blood pressure monitoring is recommended to avoid hypotension (SBP < 110 mmHg), as suggested by the American Journal of Kidney Diseases guidelines 3
• Be vigilant for symptoms of electrolyte abnormalities such as fatigue, muscle cramps, or light-headedness, as advised by the American Journal of Kidney Diseases guidelines 3

Dosing and Administration

• Patients should be instructed to hold or reduce chlorthalidone doses during periods of decreased oral intake, vomiting, or diarrhea to prevent volume depletion and acute kidney injury, as recommended by the American Journal of Kidney Diseases guidelines 3
• Chlorthalidone is a thiazide-like diuretic that acts on the distal tubule by inhibiting sodium and chloride reabsorption, according to the American Academy of Pediatrics 4

Combination Therapy

• Chlorthalidone can be combined with loop diuretics in advanced CKD for effective volume and BP control, with a longer duration of action than hydrochlorothiazide, providing better 24-hour BP control, as suggested by the Hypertension journal 5
• The American College of Cardiology recommends combining chlorthalidone with other antihypertensive agents, such as IECA or ARA-II, calcium channel blockers, beta blockers, or spironolactone, for improved blood pressure control 6, 4
• Chlorthalidone can be effectively combined with other antihypertensive medications, such as ACE inhibitors, ARBs, calcium channel blockers, and beta-blockers, as suggested by the American Heart Association 7
• Spironolactone can be added to chlorthalidone therapy to prevent sympathetic activation and insulin resistance, with a recommended dose of 25-50 mg/day, as suggested by the American College of Cardiology and the American Heart Association 8

Special Considerations

• The American College of Rheumatology conditionally recommends switching from hydrochlorothiazide to an alternate antihypertensive when feasible for patients with gout, due to the risk of hyperuricemia and gout flares associated with chlorthalidone 9
• Losartan is conditionally recommended as a preferred antihypertensive for patients with gout due to its uricosuric effects, as suggested by the American College of Rheumatology 9
• Prophylactic therapy with low-dose colchicine or NSAIDs may be considered in high-risk patients starting chlorthalidone who cannot use alternative antihypertensives, as suggested by the American College of Physicians 10
• Use chlorthalidone with caution in patients with a history of gout, as recommended by the American Heart Association 11

Lifestyle Modifications

• The American Heart Association recommends a sodium restriction of less than 2 g/day, a DASH or Mediterranean-style diet, regular physical activity, limited alcohol consumption, and maintaining a healthy weight to help manage hypertension 1
• A DASH or Mediterranean diet is recommended to reduce blood pressure, with increased consumption of vegetables, fruits, low-fat dairy, whole grains, and reduced saturated fat and cholesterol intake, along with regular aerobic exercise, resistance training, and a BMI of 20-25 kg/m² 2
• The American Heart Association recommends a target BP of 120-129/<80 mmHg for most adults, and a target range of 130-139 mmHg systolic for patients ≥65 years, with more lenient targets (e.g., <140/90 mmHg) for patients ≥85 years or with frailty 2

Medication Recommendations

Adverse Effects

• The risk of hypokalemia is higher with chlorthalidone (HR 2.72) compared to hydrochlorothiazide, according to the National Kidney Foundation 12
• Chlorthalidone may worsen glucose control and increase the risk of type 2 diabetes (HR 1.21), as reported by the American Diabetes Association 12
• The American College of Cardiology suggests being aware that chlorthalidone has a significantly higher risk of hypokalemia compared to hydrochlorothiazide, with a 3.06 times higher risk of hospitalization for hypokalemia, based on moderate-quality evidence 13